AMENDMENT TO COLLABORATION, LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • August 4th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This Amendment to the Collaboration, License, Development and Commercialization Agreement (this “Amendment”), effective as of April 28, 2017, (the “Effective Date”) is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (“Aratana”) and Eli Lilly and Company, an Indiana corporation, operating on behalf of its Elanco Animal Health division and having its office at 2500 Innovation Way, Greenfield, Indiana 46140 and its Affiliates (“Elanco”).
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 4th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to Loan and Security Agreement (the “Amendment”) is entered into as of July 31, 2017, by and among Pacific Western Bank, a California state chartered bank (“PWB”), in its capacity as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Agreement (as defined below) or otherwise a party thereto from time to time, including PWB in its capacity as a Lender and Oxford Finance LLC, a Delaware limited liability company (each a “Lender” and collectively, the “Lenders”), and Aratana Therapeutics, Inc., a Delaware corporation (“Parent”) and Vet Therapeutics, Inc., a Delaware corporation (individually and collectively, jointly and severally, “Borrower”).
